BioSyent Inc. (BIOYF) Stock Price & Analysis
BioSyent Inc. (BIOYF) — price $12.14 (-2.72%), as of the Nov 19, 2026 trading session; market cap $136M.
Educational signal · not a buy or sell recommendation · How to read this
BioSyent Inc. · BIOYF
BioSyent Inc. is a Canadian specialty pharmaceutical company that sources, acquires, develops, and sells a range of pharmaceutical and healthcare products globally. Its portfolio includes iron supplements, women's health products, pain management, and other specialty therapeutics distributed through wholesalers and retail pharmacies.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.14 | |
| Change on the day | -2.72% | |
| 52-week range | $7.66 – $12.73 | |
| Market capitalisation | $136M | — |
| Price / earnings (trailing) | 20.57 | |
| Shares traded on the day | 1.8K |
Price & events
Other perspectives
Council score for BioSyent (BIOYF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioSyent (BIOYF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioSyent Inc. (BIOYF) is the company analyzed here. It employs 711 people and is led by René C. Goehrum. In Q2 FY2026 it reported revenue of C$20M and net income of C$3M. The market values it at $136M.
What do the latest results show for BioSyent (BIOYF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of C$20M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | C$20M | C$3M | C$0.25 (diluted) |
| Q1 FY2026 | C$14M | C$2M | C$0.20 (diluted) |
| Q4 FY2025 | C$10M | C$2M | C$0.18 (diluted) |
| Q3 FY2025 | C$12M | C$3M | C$0.23 (diluted) |
What are the financial strengths and risks for BioSyent (BIOYF)?
Short answer · as of
The distress and quality screens read Altman Z 11.03 · Piotroski F 5. Trailing ratios: ROE 22.9% · ROA 16.3% · current ratio 2.07 · earnings yield 4.9% · free-cash-flow yield 5.9%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BIOYF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BIOYF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
BioSyent Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the BIOYF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BIOYF a good stock to buy?
Stock Expert AI does not rate BIOYF buy, sell or hold. BioSyent Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BIOYF stock price today?
The last price recorded for BioSyent Inc. (BIOYF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key market segments BioSyent Inc. targets with its pharmaceutical products?
BioSyent Inc. targets several key market segments within the healthcare sector with its specialized pharmaceutical products. A primary focus is on individuals suffering from iron deficiency anemia, addressed by its FeraMAX product line.
What are the key factors to evaluate for BIOYF?
Evaluate BIOYF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does BIOYF data refresh on this page?
BIOYF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BIOYF's recent stock price performance?
BioSyent Inc. (BIOYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio addressing various medical needs, reducing reliance on a single product. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOYF overvalued or undervalued right now?
The trailing P/E of BioSyent Inc. (BIOYF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BIOYF before investing?
Before investing in BioSyent Inc. (BIOYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com